01 / 06
NGS
NGS Technology Advancement
CRISPR screens, ATAC-seq, ChIP-seq, single-cell RNA-seq, RNA metabolism — interpreted with mechanism in mind.
Lexington, MA Est. 2025
First Wave Discovery partners with early-stage biotechs, small pharma, and scientific Founders — helping their teams credential targets, design translational programs, and operate the discovery engine with the discipline of senior in-house leadership.
First Wave partners across the early-discovery cycle - from target hypothesis and biomarker identification through program launch and drug discovery. Engagements are scoped to a single discipline or spanned across multiple domains.
CRISPR screens, ATAC-seq, ChIP-seq, single-cell RNA-seq, RNA metabolism — interpreted with mechanism in mind.
Hypothesis to defensible target package — ranked, scored, and ready for diligence.
Discovery assays and cascades scoped to the biology and chemistry at hand.
Evaluating and de-risking a startup's viability, assets, and programs.
Discovery-engine operations, CRO orchestration, and decision-grade milestones.
Biomarker discovery, patient stratification, and bench-to-clinic correlate maps.
CRISPR screens, ATAC-seq, ChIP-seq, single-cell RNA-seq, RNA metabolism — interpreted with mechanism in mind.
Hypothesis to defensible target package — ranked, scored, and ready for diligence.
Discovery assays and cascades scoped to the biology and chemistry at hand.
Evaluating and de-risking a startup's viability, assets, and programs.
Discovery-engine operations, CRO orchestration, and decision-grade milestones.
Biomarker discovery, patient stratification, and bench-to-clinic correlate maps.